ClinicalTrials.gg
Sign In
CompletedNCT00753051TCRSUpdated May 7, 2012

Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)

An interventional study of clozapine+haloperidol and clozapine,electroconvulsive therapy in Schizophrenia, sponsored by Khon Kaen University. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-07.

Sponsored by Khon Kaen University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Clozapine treatment resistant schizophrenia is still prevalent.The effectiveness of augmenting clozapine : one augmenting with haloperidol and the other with electroconvulsive therapy should be determined.This study is a randomized control trial.

02

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • clozapine-resistant schizophrenics
  • haloperidol augmenting clozapine
  • electroconvulsive therapy augmenting clozapine
03

In context

Schizophrenia

3,539 studies on the registry are indexed under Schizophrenia; 473 are open to participants now.

This study's enrollment of 18 is below the median of 70 across 2,924 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Khon Kaen University is the lead sponsor of 161 studies on the registry; 24 are open to participants now.

Browse Khon Kaen University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. schizophrenic patients diagnosed with schedules for clinical assessment in neuropsychiatry ( SCAN )in accordance with DSM-IV-TR or ICD-10
  2. Resistant to at least 6 weeks of clozapine treatment in therapeutic dosage
  3. Voluntary to participate the research protocol expressed by signing informed consent form

Exclusion criteria

Exclusion Criteria:

  1. Patient does not volunteer himself or herself
  2. Patient is having epilepsy, DM, cardiac disease, autistic disorder and illiterate
  3. Patient is deaf, blind , dumb to obstruct good communication
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    1.

    clozapine as the main agent and it will be adjuncted by haloperidol

    Drug: clozapine+haloperidol

  • Active comparator
    2.

    clozapine as the main agent and it will be adjuncted by electroconvulsive therapy

    Drug: clozapine,electroconvulsive therapy

Interventions

  • Drugclozapine+haloperidol

    Drug pages: Clozapine · Haloperidol

    clozapine 300-900 mg/d haloperidol 4-60 mg/d

    Also known as: clopaze, haloperidol

  • Drugclozapine,electroconvulsive therapy

    Drug page: Clozapine

    clozapine 300-900 mg/d electroconvulsive therapy 4-12 times

    Also known as: clopaze , Thymatron ECT machine

06

What researchers measure

Primary outcomes

  1. PANSS , HAM-D , CGI , AIMS Scores

    Time frame: every 4 weeks for 24 weeks

07

Study locations

1 site
  • Department of Psychiatry.Faculty of Medicine.KhonKaen University.
    Muang, KhonKaen 40002, Thailand
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00753051
Lead sponsor
Khon Kaen University
Responsible party
Suchat Paholpak (Professor Doctor, Khon Kaen University) — Principal investigator
First posted
Sep 16, 2008
Start date
Jun 2008
Primary completion
Mar 2012
Completion
May 2012
Last update
May 7, 2012

Study contacts

Suchat Paholpak, MD
principal investigator · Department of Psychiatry.Faculty of Medicine.Khon Kaen University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clozapine · Haloperidol

Other studies in this condition

Schizophrenia →

Other studies from this sponsor

Khon Kaen University →

Start the discussion